NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis $7.81 +0.35 (+4.69%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.03▼$7.9950-Day Range$6.49▼$9.9952-Week Range$3.26▼$10.03Volume1.35 million shsAverage Volume896,614 shsMarket Capitalization$505.15 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Terns Pharmaceuticals alerts: Email Address Terns Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside72.9% Upside$13.50 Price TargetShort InterestHealthy3.75% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.64Based on 7 Articles This WeekInsider TradingSelling Shares$556,938 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.31) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.44 out of 5 starsMedical Sector86th out of 910 stocksPharmaceutical Preparations Industry33rd out of 426 stocks 3.4 Analyst's Opinion Consensus RatingTerns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTerns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Terns Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.75% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 32.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTerns Pharmaceuticals has received a 58.77% net impact score from Upright. Terns Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Terns Pharmaceuticals is -0.95. Previous Next 2.6 News and Social Media Coverage News SentimentTerns Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Terns Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows3 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $556,938.00 in company stock.Percentage Held by Insiders15.10% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.31) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And this fear has caused the entire crypto market to plunge. But everyone is forgetting one thing…Bitcoin was created in the aftermath of the 2008 financial crisis. Click here to reserve your spot at the emergency crypto summit now. About Terns Pharmaceuticals Stock (NASDAQ:TERN)Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Read More TERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TERN Stock News HeadlinesSeptember 7 at 1:39 AM | americanbankingnews.comTerns Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:TERN)September 6 at 5:27 PM | msn.comMicron, Oracle are new Top Picks at MizuhoSeptember 8, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... September 5 at 2:49 AM | americanbankingnews.comJMP Securities Reiterates Market Outperform Rating for Terns Pharmaceuticals (NASDAQ:TERN)August 29, 2024 | forbes.comThe Obesity Treatment Boom: Is This Only The Beginning?August 24, 2024 | finance.yahoo.comTerns Pharmaceuticals Inc. (US8808811074.SG)August 22, 2024 | markets.businessinsider.comAnalyst Forecasts Terns Pharmaceuticals’ Upcoming CML Trial Data as Catalyst for GrowthAugust 7, 2024 | markets.businessinsider.comBuy Rating for Terns Pharmaceuticals Amid Forthcoming Milestones and Financial StabilitySeptember 8, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Terns Pharmaceuticals Amidst Promising Trials and Strong Financial FootingAugust 6, 2024 | markets.businessinsider.comBuy Rating Affirmed on Terns Pharmaceuticals Ahead of Key Clinical Data Releases and Strong Financial StandingAugust 6, 2024 | finance.yahoo.comTerns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate UpdatesAugust 4, 2024 | msn.comNew anti-obesity pills threaten Eli Lilly and Novo Nordisk’s stock market empireAugust 2, 2024 | investorplace.com3 Biotech Stocks That Could Have Investors Grinning SoonJuly 31, 2024 | investing.comTerns Pharmaceuticals appoints new chief legal officerJuly 30, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO TransitionJuly 29, 2024 | globenewswire.comTerns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO TransitionJuly 20, 2024 | fool.comCan These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?See More Headlines Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TERN CUSIPN/A CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$19.00 Low Stock Price Target$5.50 Potential Upside/Downside+72.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.58% Return on Assets-37.69% Debt Debt-to-Equity RatioN/A Current Ratio21.02 Quick Ratio21.02 Sales & Book Value Annual Sales$1 million Price / Sales505.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book2.31Miscellaneous Outstanding Shares64,680,000Free Float54,911,000Market Cap$505.15 million OptionableNot Optionable Beta-0.37 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Erin Quirk M.D. (Age 53)President & Head of Research & Development Comp: $1.06MDr. Mark Joseph Vignola Ph.D. (Age 46)CFO & Treasurer Comp: $974.16kMr. Seokho Yoon Esq. (Age 46)COO, General Counsel & Secretary Comp: $921.05kMs. Amy L. Burroughs M.B.A. (Age 53)CEO & Director Dr. Jeffrey R. Jasper Ph.D.Senior VP & Head of ResearchDr. Emil T. Kuriakose M.D. (Age 44)Chief Medical Officer Ms. Melita Sun Jung (Age 47)Chief Business Officer More ExecutivesKey CompetitorsAquestive TherapeuticsNASDAQ:AQSTInozyme PharmaNASDAQ:INZYEnanta PharmaceuticalsNASDAQ:ENTAIntercept PharmaceuticalsNASDAQ:ICPTEnzo BiochemNYSE:ENZView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 469,176 shares on 8/19/2024Ownership: 4.160%The Manufacturers Life Insurance Company Bought 5,049 shares on 8/15/2024Ownership: 0.035%Great Point Partners LLCSold 160,569 shares on 8/14/2024Ownership: 1.777%Marshall Wace LLPSold 160,024 shares on 8/14/2024Ownership: 0.040%Hsbc Holdings PLCSold 3,815 shares on 8/12/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions TERN Stock Analysis - Frequently Asked Questions How have TERN shares performed this year? Terns Pharmaceuticals' stock was trading at $6.49 on January 1st, 2024. Since then, TERN stock has increased by 20.3% and is now trading at $7.81. View the best growth stocks for 2024 here. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) issued its earnings results on Monday, August, 5th. The company reported ($0.31) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.04. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Top institutional investors of Terns Pharmaceuticals include Point72 Asset Management L.P. (4.16%), Great Point Partners LLC (1.78%), Dimensional Fund Advisors LP (0.57%) and Salem Investment Counselors Inc. (0.57%). Insiders that own company stock include Orbimed Advisors Llc, Hongbo Lu, Biosciences Fund V LP Lav, Vivo Opportunity, Llc and Jill M Quigley. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TERN) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
